Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease

Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavedo, Enrica, Grothe, Michel J., Colliot, Olivier, Lista, Simone, Chupin, Marie, Dormont, Didier, Houot, Marion, Lehéricy, Stephane, Teipel, Stefan, Dubois, Bruno, Hampel, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601919/
https://www.ncbi.nlm.nih.gov/pubmed/28916821
http://dx.doi.org/10.1038/s41598-017-09780-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601919/
https://www.ncbi.nlm.nih.gov/pubmed/28916821
http://dx.doi.org/10.1038/s41598-017-09780-3

Ejemplares similares